Lexicon Pharmaceuticals Stock (NASDAQ:LXRX)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$0.72

52W Range

$0.62 - $3.73

50D Avg

$1.22

200D Avg

$1.69

Market Cap

$258.36M

Avg Vol (3M)

$4.00M

Beta

1.24

Div Yield

LXRX Company Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

285

IPO Date

Apr 07, 2000

Website

LXRX Performance

LXRX Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	$1.20M	$139.00K	$298.00K
Operating Income	$-171.75M	$-100.76M	$-87.09M
Net Income	$-175.61M	$-103.13M	$-88.27M
EBITDA	$-171.75M	$-99.16M	$-86.96M
Basic EPS	$-0.79	$-0.62	$-0.61
Diluted EPS	$-0.79	$-0.62	$-0.61

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q3 24Nov 12, 24 | 8:39 PM

Q2 24Aug 01, 24 | 11:00 PM

Q1 24May 02, 24 | 12:00 AM

Peer Comparison

Ticker	Company
DAWN	Day One Biopharmaceuticals, Inc.
HOOK	HOOKIPA Pharma Inc.
MCRB	Seres Therapeutics, Inc.
XFOR	X4 Pharmaceuticals, Inc.
IBRX	ImmunityBio, Inc.
MREO	Mereo BioPharma Group plc
BLRX	BioLineRx Ltd.
ARDX	Ardelyx, Inc.
ELEV	Elevation Oncology, Inc.
TERN	Terns Pharmaceuticals, Inc.
OCEA	Ocean Biomedical, Inc.
HEPA	Hepion Pharmaceuticals, Inc.
ENVB	Enveric Biosciences, Inc.